FLUVOXAMINE TEVA  100 MG Israel - English - Ministry of Health

fluvoxamine teva 100 mg

teva pharmaceutical industries ltd, israel - fluvoxamine maleate - tablets - fluvoxamine maleate 100 mg - fluvoxamine - for the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. treatment of obsessive compulsive disorders (ocd).

CO-DIOVAN 8012.5 MG FILM COATED TABLETS Israel - English - Ministry of Health

co-diovan 8012.5 mg film coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

CO-DIOVAN 16012.5 MG FILM-COATED TABLETS Israel - English - Ministry of Health

co-diovan 16012.5 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

CO-DIOVAN 16025 MG FILM-COATED TABLETS Israel - English - Ministry of Health

co-diovan 16025 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

LOTAN PLUS Israel - English - Ministry of Health

lotan plus

unipharm ltd, israel - hydrochlorothiazide; losartan potassium - tablets - losartan potassium 50 mg; hydrochlorothiazide 12.5 mg - lotan plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.

LOTAN 100 Israel - English - Ministry of Health

lotan 100

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 100 mg - losartan - hypertension: lotan 100 is indicated for the treatment of hypertension. heart failure:lotan 100 is indicated for the treatment of heart failure, when treatment with an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to lotan 100 is not recommended. renal protection in type-2 diabetic patients with proteinuria: lotan 100 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. lotan 100 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of lotan 100 on the

LOTAN 12.5 Israel - English - Ministry of Health

lotan 12.5

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 12.5 mg - losartan - heart failure: lotan 12.5 is indicated for the treatment of heart failure, when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to lotan 12.5 mg is not recommended

LOTAN 50 Israel - English - Ministry of Health

lotan 50

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 50 mg - losartan - hypertension: lotan 50 mg is indicated for the treatment of hypertensionheart failure: lotan 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to lotan 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: lotan 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. lotan 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventri

SULFAMETHOPRIM PREMIX VETERINARY Israel - English - Ministry of Health

sulfamethoprim premix veterinary

abic veterinary products ltd - sulphadiazine; trimethoprim - powder - sulphadiazine 250 mg/g; trimethoprim 50 mg/g - for the treatment of infections caused by susceptible bacteria in broiler chicken, turkeys, pre-ruminating calves and fish.

PHYSIONEAL 40 GLUCOSE 1.36 % WV Israel - English - Ministry of Health

physioneal 40 glucose 1.36 % wv

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; lactic acid as sodium 1.68 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 13.6 g/l; calcium chloride dihydrate 0.184 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.